130 Results for "

c-Kit inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (130)

130 Results for "c-Kit inhibitor" in MCE Product Catalog:

  • Targets Recommended:
161
161 Publications Verification
Cat. No.: HY-16749
CAS No.: 1029044-16-3
Synonyms: PLX-3397
Target:  

c-Fms c-Kit Apoptosis

Research Areas:  

Cancer

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity. Pexidartinib has limited permeability to the blood-brain barrier, primarily through ABCB1 .
loading...
    loading...
161
161 Publications Verification
Cat. No.: HY-16749A
CAS No.: 2040295-03-0
Synonyms: PLX-3397 hydrochloride
Target:  

c-Fms c-Kit Apoptosis

Research Areas:  

Cancer

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity .
loading...
    loading...
127
127 Cited Publications
Cat. No.: HY-15463
CAS No.: 152459-95-5
Purity:  99.95%
Synonyms: STI571; CGP-57148B
Research Areas:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
127
127 Cited Publications
Cat. No.: HY-50946
CAS No.: 220127-57-1
Synonyms: STI571 Mesylate; CGP-57148B Mesylate
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
loading...
    loading...
41
41 Cited Publications
Cat. No.: HY-10514
CAS No.: 702675-74-9
Purity:  99.84%
Target:  

PDK-1 IKK Autophagy

Research Areas:  

Cancer

BX795 is a potent and selective inhibitor of PDK1, with an IC50 of 6 nM. BX795 is also a potent and relatively specific inhibitor of TBK1 and IKKε, with an IC50 of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy .
loading...
    loading...
39
39 Cited Publications
Cat. No.: HY-10230
CAS No.: 120685-11-2
Purity:  99.91%
Synonyms: PKC412; CGP 41251
Research Areas:  

Cancer

Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-10208
CAS No.: 444731-52-6
Purity:  99.91%
Synonyms: GW786034
Research Areas:  

Cancer

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-12009
CAS No.: 635702-64-6
Purity:  99.99%
Synonyms: GW786034 Hydrochloride
Research Areas:  

Cancer

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-10205
CAS No.: 288383-20-0
Purity:  99.87%
Synonyms: AZD2171
Cediranib (AZD2171) is a highly potent, orally available and blood-brain barrier permeability VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-13049
CAS No.: 857036-77-2
Purity:  99.95%
Synonyms: AZD-2171 maleate
Target:  

VEGFR Autophagy PDGFR

Research Areas:  

Cancer

Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-10207
CAS No.: 692737-80-7
Purity:  99.75%
Synonyms: CHIR-258 lactate; TKI-258 lactate
Target:  

FLT3 c-Kit FGFR VEGFR PDGFR

Research Areas:  

Cancer

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-50905
CAS No.: 405169-16-6
Synonyms: CHIR-258; TKI258
Target:  

FLT3 c-Kit FGFR VEGFR PDGFR c-Fms

Research Areas:  

Cancer

Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10206
CAS No.: 850879-09-3
Purity:  99.40%
Synonyms: MP470; HPK 56
Research Areas:  

Cancer

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-101443
CAS No.: 945526-43-2
Purity:  98.92%
Target:  

c-Kit

Research Areas:  

Inflammation/Immunology

ISCK03 is a SCF/c-Kit and CD117-specific inhibitor. ISCK03 significantly inhibits c-Kit phosphorylation at 10 μM .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-10209
CAS No.: 790299-79-5
Purity:  99.95%
Synonyms: AB1010
Research Areas:  

Cancer

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-10209A
CAS No.: 1048007-93-7
Purity:  99.51%
Synonyms: AB-1010 mesylate
Target:  

c-Kit PDGFR Src FGFR Apoptosis

Research Areas:  

Cancer

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-10202
CAS No.: 387867-13-2
Purity:  99.48%
Synonyms: MLN518; CT53518
Target:  

FLT3 c-Kit PDGFR Apoptosis

Research Areas:  

Cancer

Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-10202A
CAS No.: 2438900-70-8
Purity:  99.78%
Synonyms: MLN518 hydrochloride; CT53518 hydrochloride
Target:  

FLT3 c-Kit PDGFR Apoptosis

Research Areas:  

Cancer

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10408
CAS No.: 623142-96-1
Purity:  99.51%
Target:  

c-Fms VEGFR c-Kit PDGFR

Research Areas:  

Inflammation/Immunology

Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13904
CAS No.: 895519-90-1
Purity:  99.85%
Synonyms: HHGV678
Target:  

Bcr-Abl c-Kit PDGFR

Research Areas:  

Cancer

Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively .
loading...
    loading...